Sikander Ailawadhi, MD

Professor of Medicine; Lead, International Cancer Center
Department of Cancer Biology, Mayo Clinic

Poster(s):

• 1436 - Real-World Treatment Utilization Patterns, Discontinuation and Healthcare Resource Utilization of First-Line (1L) Bruton Tyrosine Kinase Inhibitor (BTKi) Therapy in Chronic Lymphocytic Leukemia (CLL): Age-Related Disparity

• 1911 - Prospective Patient Preference Study for Chronic Lymphocytic Leukemia (CLL) Treatment Attributes Impacting Patient Shared-Decision Making